Why Having Tattoos Poses a Real Cancer Risk
Tattoos have never been more popular. From delicate finger flowers to full-body suits, ink has become a mainstream form of self-expression.
But a striking new study from Sweden’s Lund University raises a provocative question: could your body art be quietly raising your cancer risk?
According to research published in the European Journal of Epidemiology, people with tattoos face a 29% higher relative risk of developing cutaneous melanoma—a dangerous and potentially deadly form of skin cancer—compared to people without tattoos.
Let’s pause right there. A 29% increase sounds alarming. But before you start regretting that mermaid on your forearm, let’s dig into what the scientists actually found.
More Than Skin Deep
The Lund team, led by researchers Rietz Liljedahl, Nielsen, Engfeldt, and Nielsen, didn’t just compare inked people to non-inked people and call it a day. They carefully accounted for major confounding factors—like sun exposure habits and natural skin type—two of the biggest known drivers of melanoma risk.
Even after crunching those numbers, the tattoo-cancer link remained.
But here’s where things get weird: the size of the tattoo didn’t seem to matter. A tiny butterfly on your ankle carried roughly the same statistical risk as a full sleeve. That suggests the issue may not be how much ink you have, but simply that you have ink at all.
Timing Is Everything
The study uncovered another intriguing clue: the danger appears highest within the first 10 to 15 years after getting tattooed. After that window, the risk seems to stabilize—though it doesn’t disappear entirely.
Why would the timing matter? Scientists suspect the body’s initial immune response to tattoo ink could play a role. When ink is injected into the skin, your immune system recognizes the pigment particles as foreign invaders. Those particles don’t just sit still—they can migrate through the body, eventually lodging in the lymph nodes (diagram, below), which are key hubs of immune activity.
The Inflammation Hypothesis
The researchers propose a biological explanation that makes sense on paper: chronic, low-grade inflammation triggered by the presence of tattoo ink could, over years, nudge cells toward cancerous changes. Some ink pigments also contain potentially carcinogenic chemicals, and when those particles travel to lymph nodes, they may set up a long-term irritant effect in tissues responsible for filtering and defending the body.
Interestingly, people with both black and colored pigments faced a notably higher risk than those with only one type. That suggests that certain ink formulations—especially colorful ones—might be more problematic than others.
What This Study Doesn’t Say
Let’s be clear: correlation is not causation. The study does not prove that tattoos cause cancer. It’s possible that people who get tattoos also share other behaviors or environmental exposures that raise melanoma risk—though the researchers did their best to control for sun exposure and skin type.
It’s also worth noting that melanoma is still relatively rare. A 29% higher relative risk sounds dramatic, but the absolute risk for an individual remains low. For context, if the baseline lifetime risk of melanoma is about 1 in 50 (2%), a 29% increase would raise it to roughly 2.6%. So the vast majority of people with tattoos will never develop melanoma.
The Bottom Line
As tattoos become more ubiquitous, studies like this one are a wake-up call. We know surprisingly little about the long-term biological effects of injecting industrial-grade pigments into our bodies. The Lund research doesn’t sound the alarm for panic—but it does sound the alarm for more research.
In the meantime, if you’re inked or planning to be, consider this: keep an eye on your skin, watch for changing moles or spots, and don’t skip those dermatology checkups. Your tattoos might be art—but your health is science.
*Reference: Rietz Liljedahl, E., Nielsen, K., Engfeldt, M., & Nielsen, C. (2025). Does tattoo exposure increase the risk of cutaneous melanoma? A population-based case-control study. European Journal of Epidemiology.*